This MedLibrary.org supplementary page on Vorinostat is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Vorinostat
|
|
| Systematic (IUPAC) name | |
| N-hydroxy-N'-phenyl-octanediamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C14H20N2O3 |
| Mol. mass | 264.32 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 71% |
| Metabolism | Hepatic glucuronidation and oxidation CYP system not involved |
| Half life | 2 hours |
| Excretion | Renal (negligible) |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. |
D(US) |
| Legal status | |
| Routes | Oral |
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA) is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities. SAHA is marketed under the name Vorinostat, brand name Zolinza, for the treatment of cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after treatment with other medicines. It has also been used to treat Sézary syndrome, another type of lymphoma closely related to CTCL.1
A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.
Zolinza was approved by the U.S. Food and Drug Administration (FDA) for the treatment of CTCL on October 6, 2006, and it is manufactured by Patheon, Inc., in Mississauga, Ontario, Canada, for Merck & Co., Inc., White House Station, New Jersey.
References
- ^ Cuneo A, Castoldi. "Mycosis fungoides/Sezary's syndrome". Retrieved on 2008-02-15.
- Merck & Co. (June 7, 2006). "ZOLINZA, Merck's Investigational Medicine for Advanced Cutaneous T-Cell Lymphoma (CTCL), To Receive Priority Review from U.S. Food and Drug Administration". Press release. Retrieved on 6 October 2006.
- Food and Drug Administration (October 6, 2006). "FDA Approves New Drug for Skin Cancer, Zolinza". Press release. Retrieved on 6 October 2006.
- Mayo Clinic (June 3, 2007). "Vorinostat shows anti-cancer activity in recurrent gliomas". Press release. Retrieved on 3 June 2007.
See also
|
||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Wikipedia content modification information:
- This page was last modified on 28 October 2008, at 01:48.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Vorinostat".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.